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With increasing information on genome, transcriptome
and metabolome of commonly used production cell
lines, engineering becomes an increasingly popular
approach to achieve desired product attributes, growth
behavior and nutrient consumption. Tools range from
feeding intermediate metabolites, overexpression or
deregulation of key enzymes of a pathway to knock-out
and RNA silencing. While conceptionally simple, the lat-
ter approaches are either labor intensive or costly to
apply at large scale.
Fucose targeted glycoengineering
Aiming at glycan modulation we added another princi-
ple to this toolbox: enzymatic deflection of a biochem-
ical pathway. Fucose is synthesized inside the cell from
GDP-mannose via short lived intermediates before it is
transported to the Golgi apparatus for attachment to
the nascent glycan (Figure 1). A bacterial enzyme is
used to redirect synthesis towards a heterologous acti-
vated hexose that cannot be utilized by the cell resulting
in depletion of the natural pathway (deflecting enzyme,
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Figure 1 Overview of GDP-L-Fucose Biosynthesis showing the point of substrate deflection within the fucose de-novo synthesis pathway.
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any medium, provided the original work is properly cited.Figure 1). To our surprise, even lowest level expression
of the enzyme completely abolishes fucose synthesis in
stably modified cells.
The approach allows producing antibodies that are
devoid of core fucose at Fc glycans of the CH2 domain
[1]. This modification provides higher flexibility to the
Fc-region of IgG1 antibodies and enhances their binding
to the FcgRIIIa receptor of NK cells - the dominating
effector cells in antibody dependent cytotoxicity
(ADCC). Consequently, the potency of antibodies direc-
ted against tumor or infected cells is substantially
increased.
In contrast to other strategies the approach is easily
applied to the starter cell line of choice and, moreover,
allows modification of fully developed producer cell
lines within weeks.
Simultaneous regulation of multiple cellular
pathways
Another concept for clone engineering is based on
simultaneous modulation of multiple cellular processes.
We found that the Rho GTPase cdc42 is a highly suita-
ble effector molecule for this purpose. This pleiotropic
modulator dramatically boosts antibody titers when
overexpressed in the cytosol of pharmaceutical producer
clones (Table1).
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Table 1 CDC42-mediated relative mAb-titer increase over
native clone titers. The clones represent five different
products.
Titers of Naïve
mAb producing
clones
[g/l]
Titers of cdc42-
engineered mAb
producing clones
[g/l]
Relative Fold
Increase per
modified clone
0,8 1,65 2,06
0,9 2,2 2,4
2,3 3,0 1,3
2,6 4,5 1,73
0,8 1,65 2,06
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